Syntara Limited · ASX:SNT
Syntara — Investor Presentation (June 2026)
20 slides from Syntara's investor presentation, Jun 1, 2026
Slide 1: SNT-4728 Webinar
For personal use only SNT-4728 Webinar Gary Phillips, CEO 1st June 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT For personal use only This document contains These forward-looking forward-looking statements, statements are not guarantees including statements or predictions of future results, concerning Syntara’s future levels of performance, and financial position, plans, and the invo
Slide 3: SNT-4728 phase 2a study webinar participants
SNT-4728 phase 2a study – Webinar Participants For personal use only Professor Simon Lewis Dr Lynsey Bilsland Gary Phillips Dr Wolfgang Jarolimek Trial Principal Investigator MD, Parkinson’s CEO Head Drug Discovery Research Ventures Ltd • Neurologist sub-specialised in • More than 30 years • More th
Slide 4: SNT-4728 phase 2a study webinar agenda
SNT-4728 phase 2a study - Webinar 1. SNT-4728: a brief history – Gary Phillips For personal use only 2. iRBD and Parkinson’s disease – Dr Lynsey Bilsland • The facts • Patient perspective 3. Neuroinflammation – Dr Wolfgang Jarolimek • Role of neuroinflammation in iRBD and Parkinson’s disease • SNT-4
Slide 5: SNT-4728: Brief History
SNT-4728: BRIEF HISTORY SNT-4728 FOR NEUROINFLAMMATION Safe and efficacious, small molecule enzyme inhibitor that crosses the For personal use only blood brain barrier A novel approach • Syntara discovered and wholly • Strong preclinical and clinical owned asset data support the role of SSAO • Drug
Slide 6: iRBD and Parkinson's disease
SNT-4728 Webinar Participants For personal use only Dr Lynsey Bilsland iRBD and Parkinson’s disease • The facts • MD, Parkinson’s Research Ventures Ltd • Patient perspective 6
Slide 7: iRBD and Parkinson's Key Facts
iRBD AND PARKINSON’S Using a sleep disorder to target Parkinson’s. KEY FACTS Early intervention to demonstrate neuroprotection – rather than late treatment when most neurons have already been lost (for example in PD) – is where disease-modifying, For personal use only • Patients with isolated REM sl
Slide 8: Parkinson's UK and patient perspective
PARKINSON’S UK Largest European funder of Parkinson’s research For personal use only By 2050, the number of people living with Parkinson’s worldwide will double to 25 million. Joe describes what it’s like to live with iRBD: ● There are no treatments that can "I depend on my wife telling me of my res
Slide 9: Parkinson's Research Ventures
PARKINSON’S RESEARCH Early intervention in the prodromal phase of Parkinson's, which VENTURES Syntara is pioneering with SNT-4728, could be an absolute game- changer. ● Specialised global programme, in For personal use only If we could identify people up to 20 years before their Parkinson’s partners
Slide 10: Neuroinflammation
SNT-4728 Webinar Participants For personal use only Dr Wolfgang Jarolimek Neuroinflammation • Role of neuroinflammation in iRBD and PD Head of Drug Discovery, Syntara • SNT-4728: how it works 10
Slide 11: Vicious Cycle: Neuroinflammation drives neurodegeneration
Reactive oxygen VICIOUS CYCLE species Neuroinflammation drives neurodegeneration For personal use only • Neurodegeneration is sustained by a self-reinforcing cycle of oxidative stress, mitochondrial dysfunction Cellular Mitochondrial Microglial and microglial activation. dysfunction Activation • The
Slide 12: SSAO and MAO-B Drive Neuroinflammation
SSAO and MAO-B DRIVE NEUROINFLAMMATION For personal use only Protein Crosslinking Toxicity Inflammation Substantia nigra α-synuclein (midbrain) Toxic products + Cytotoxicity Mitochondrial Primary toxicity reactive oxygen DNA damage amines species (H₂O₂) MAO-B SSAO α-synuclein Caspases aggregation En
Slide 13: Transition into the Clinic
TRANSITION INTO THE CLINIC Microglial activation as a biomarker for neuroinflammation - LPS activates microglia PD patients have increased microglial For personal use only - SSAO inhibitor reduces microglial activation1 activation GFAP: glial fibrillary acidic protein SSAO inhibitor GFAP: glial fibr
Slide 14: SNT-4728 Clinical Trial
SNT-4728 Webinar Participants For personal use only Prof Simon Lewis SNT-4728 Clinical Trial • Why is this study important? • Trial Principal Investigator • Design and endpoints • When are the results expected and what will they tell us? 14
Slide 15: Why Is This Study Important?
WHY IS THIS STUDY IMPORTANT? Microglial activation is linked to dopaminergic cell loss in iRBD For personal use only [11C]PK11195 PET: iRBD vs. controls Increased baseline microglial activation - Increased microglial activation in iRBD - Greater dopaminergic loss over 3 years 15
Slide 16: Clinical Trial
SNT-4728: Study funded by Parkinson’s CLINICAL TRIAL UK Virtual Biotech and is being run at sites in Sydney, Australia and Oxford, UK Phase 2 multi-centre, placebo- For personal use only controlled study assessing effect of SNT-4728 on microglia activation in patients with iRBD 40 patients (3:1 drug
Slide 17: What Can We Expect From the Results?
WHAT CAN WE EXPECT FROM THE RESULTS? PET ligand binding and Safety Digital biomarkers Biological markers For personal use only Change in microglial activation Exploratory endpoints measuring Exploratory endpoints measuring across striato-cortical regions and cognitive, motor function and inflammatio
Slide 18: SNT-4728 – importance to investors
SNT-4728 Webinar Participants For personal use only Gary Phillips SNT-4728 – importance to investors • Next steps in road to commercialisation Chief Executive Officer, Syntara • Where it fits in Syntara’s pipeline 18
Slide 19: The Year Ahead - Poised to Deliver Near Term Value
THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE TARGET DRUG INDICATION PARTNERS PHASE 1 PHASE 2 NEWS FLOW HEALTHY H1 2026 H2 2026 PATIENTS PARTICIPANTS For personal use only FDA approved development plan Myelofibrosis and partner engagement High Risk MDS Interim safety and Phase 2 initiation AZAL
Slide 20: For personal use only
For personal use only Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au gary.phillips@syntaraTX.com.au